论文部分内容阅读
目的比较拜糖平和美迪康对２型糖尿病的临床疗效。方法将单纯饮食控制或加用磺脲类药物治疗不满意的２型糖尿病人８０例，随机分为拜糖平组４８例和美迪康组３２例，疗程为１６周。结果与结论美迪康对降空腹血糖的疗效率高于拜糖平（有效率分别为９６．９％：８５．７％，显效率为７１．９％：４７．６％；Ｐ均＜０．０１），而拜糖平对降餐后２小时血糖的疗效高于美迪康（有效率分别为９７．６％：９３．８％，显效率为７１．４％：６５．６％；Ｐ＜０．０１）；两药均能明显降低ＧＨｂＡ１ｃ，拜糖平组从９．１９％±２．７８％降至６．７６％±１．３３％（Ｐ＜０．０１），美迪康组从９．２３％±１．８９％降至７．１５％±１．２４％（Ｐ＜０．０１），两药相比对降低ＧＨｂＡ１ｃ的幅度无统计学意义（Ｐ＞０．５０）。两种药物不刺激胰岛素的分泌，对肝肾功能和血脂无影响
OBJECTIVE To compare the clinical efficacy of olanzapine and meticon for type 2 diabetes mellitus. Methods Eighty patients with type 2 diabetes treated with simple diet control or with sulfonylurea were randomly divided into 48 patients treated with albic acid and 32 patients treated with meticonazole for 16 weeks. Results and Conclusion The therapeutic effect of Mexicon on fasting glucose was higher than that of omeprazole (effective rates were 96.9%, 85.7%, 71.9%, 47.6%, respectively; all P <0 .01), while the effect of albuterol on blood glucose 2 hours after meal was higher than that of Meadicon (effective rates were 97.6% and 93.8%, respectively, the effective rate was 71.4% and 65.6% respectively; P <0.01). Both drugs reduced GHbA1c significantly, from 9.19% ± 2.78% to 6.76% ± 1.33% (P <0.01) Kang group decreased from 9.23% ± 1.89% to 7.15% ± 1.24% (P <0.01). There was no significant difference between the two groups in decreasing the amplitude of GHbA1c (P> 0.50 ). Two drugs do not stimulate the secretion of insulin, no effect on liver and kidney function and blood lipids